Clinical and genetic profile of actinic prurigo in Thai patients
Official title: Multi-centred Clinico-genetic Study of Actinic Prurigo in Thailand
Run by Chulalongkorn University · NCT07055009 · Data updated 2026-11-12
This project will test whether specific HLA genetic types are linked to how actinic prurigo looks and responds to treatment in Thai people with the condition.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 47 (estimated) |
| Sponsor | Chulalongkorn University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Bangkok) |
| Status | Recruiting |
| Started | March 30, 2025 |
| Main results expected | May 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | May 12, 2026 |
| Trial ID | NCT07055009 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are Thai-ethnicity adults diagnosed with actinic prurigo who are mentally competent, can communicate and read Thai, and can attend the participating hospitals.
✕Probably not a fit
People with other photodermatoses, non-Thai ancestry, an elevated EBV viral load, or whose only abnormality is a low UVB minimal erythema dose are unlikely to benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This cross-sectional comparative project enrolls Thai patients with actinic prurigo and age-matched healthy controls to compare clinical features and genetic markers. Participants undergo full skin examinations, targeted long-read HLA sequencing, RNA extraction, and blood testing including Epstein–Barr virus viral load. The study collects clinical presentation and treatment-response data to look for associations with HLA alleles and other genetic signatures. Recruitment is coordinated across multiple collaborating hospitals with standardized diagnostic criteria and data collection methods.
Why it matters
Potential benefit: If successful, the work could help clinicians link specific HLA types to disease patterns and treatment response, enabling more personalized diagnosis and management for Thai patients.
How similar studies have gone: HLA associations with actinic prurigo and related photodermatoses have been reported in other populations, but comprehensive clinico-genetic data specific to Thai patients remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Thai ethnicity * Diagnosed with Actinic Prurigo (AP) according to the diagnostic criteria defined for this study * Mentally competent, able to communicate, and able to read Thai. * Participants receiving Thalidomide treatment must use two simultaneous methods of contraception, starting at least 4 weeks prior to initiating the medication and continuing throughout the treatment period and for at least 4 weeks after discontinuation. Exclusion Criteria: * History and physical examination findings suggestive of other photodermatoses such as Lupus erythematosus, Porphyria, or Polymorphous Light Eruption, among others. * Elevated Epstein-Barr Virus (EBV) viral load detected in blood testing (EBV viral load will be tested in all participants). * Low Minimal Erythema Dose (MED) to UVB radiation as the only abnormal finding.
Where it's running
-
Faculty of Medicine Chulalongkorn University
Bangkok, Thailand Recruiting
Study contacts
- Study coordinator: Einapak Boontaveeyuwat, MD
- Email: einapak.b@chula.ac.th
- Phone: +66922995700
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.